-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
Study coauthor Guido Eibl, MD, discussed the research and why commonly used beta-blockers may help mitigate the cancer-promoting effects of stress and obesity. https://t.co/9YfkopDVhl https://t.co/SzpUgmcEak
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
A recent study has identified glycogen as a critical factor in the progression of lung adenocarcinoma. https://t.co/4qRZN69eim #LungCancer https://t.co/YtfTHLGjqS
-
-
Mashup Score: 0Shop Talk : Oncology Times - 21 hour(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
Theodore Scott Nowicki, MD, PhD, at the David Geffen School of Medicine at UCLA, has been awarded an R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors. https://t.co/3oFHTdpscP @dgsomucla https://t.co/VKWHlhkEqY
-
-
Mashup Score: 3
In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA. MacDonald shares her inspiring journey of facing a life-changing diagnosis with strength and resilience. Discover her insights into the healthcare system, the unexpected joys she found, and her advice for others facing similar challenges.
Source: journals.lww.comCategories: General Medicine NewsTweet-
In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, about her cancer journey, her story of courage, and the advice she has for others facing similar challenges. Listen to the full #podcast here: #Survivorship https://t.co/dJasbvXKFN https://t.co/KPBu23jDWJ
-
-
Mashup Score: 5UpToDate® : Oncology Times - 1 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
Vimseltinib, a tyrosine kinase inhibitor, has been approved by the FDA for patients with tenosynovial giant cell tumor (TGCT) for whom additional surgery would cause functional limitations or severe morbidity. Read the collaboration with #UpToDate® here: https://t.co/J64pxee40O https://t.co/S6GtGgtNtA
-
-
Mashup Score: 3
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
A recent study explored a new treatment for high-grade glioma (HGG). Researchers investigated the therapeutic potential of avapritinib, a drug already FDA-approved for other conditions, in patients with HGG. https://t.co/XAAxIHsLrr https://t.co/iPdGg9usyX
-
-
Mashup Score: 3Shop Talk : Oncology Times - 2 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
Erin K. Tagai, PhD, MPH, Assistant Professor in the Cancer Prevention at @FoxChaseCancer, has received a grant from @preventcancer to fund the development of a ChatBot for patients receiving genetic testing results. https://t.co/aL5dlAyMEL https://t.co/sPMRocwLzT
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
At the 2025 ASCO Genitourinary Cancers Symposium, researchers highlighted the efficacy and safety of perioperative treatment with disitamab vedotin, and the anti-PD-1 inhibitor toripalimab, in patients with HER2-expressing #muscle-invasive #bladdercancer. https://t.co/n93o4xnIKx https://t.co/IEwqnBrNoS
-
-
Mashup Score: 5
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
#Casdatifan, an investigational #HIF-2α inhibitor, was well tolerated and showed promising early clinical activity among patients with previously treated clear cell renal cell carcinoma (#ccRCC). Read more: https://t.co/JazhnvVnvl https://t.co/PyIRtMqrlc
-
A recent study explored the somatic mutations in the gastric epithelium and their role in the development of #GastricCancer. Read it here: https://t.co/YfQR8wSmXF https://t.co/OOkNNoKDRs